OncoMatch/Clinical Trials/NCT07306156
GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms
Is NCT07306156 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GP350 CAR-T for ebv associated lymphoid neoplasms.
Treatment: GP350 CAR-T — This is a Phase 1/Phase 2 open-label, single-arm clinical study of GP350 CAR-T for Relapse/Refractory and Epstein-Barr virus infection associated lymphoid neoplasms. Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy, and an intravenous infusion of CAR-T cells. Each participant will proceed through the following study procedures: * Screening * Enrollment/Leukapheresis * Conditioning chemotherapy * CAR T treatment * Post-treatment assessment * Long-term follow-up
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: GP350 positivity (≥10% of tumor cells) (≥10% of tumor cells)
Tumor cell GP350 positivity (≥10% of tumor cells by immunohistochemistry or flow cytometry)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
ANC ≥1.0×10⁹/L; Hemoglobin >60 g/L; CD3+ T-cell count >0.5×10⁹/L; Platelet count >30×10⁹/L
Kidney function
Creatinine clearance ≥60 mL/min
Liver function
ALT/AST ≤2× ULN; Total bilirubin ≤2× ULN
Cardiac function
LVEF ≥50%, no pericardial effusion, no clinically significant ECG abnormalities; NYHA Class III or IV congestive heart failure [excluded]; Myocardial infarction or coronary artery bypass grafting within the past 6 months [excluded]; Clinically significant ventricular arrhythmia or unexplained syncope [excluded]; History of severe non-ischemic cardiomyopathy [excluded]; Cardiac insufficiency (LVEF <45%) within 8 weeks prior to apheresis [excluded]
Creatinine clearance ≥60 mL/min; ALT/AST ≤2× ULN; Total bilirubin ≤2× ULN; LVEF ≥50%, no pericardial effusion, and no clinically significant ECG abnormalities; Minimal or no pleural/ascitic fluid; Oxygen saturation ≥95%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify